FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993261710> ?p ?o ?g. }

• W2993261710 endingPage "146" @default.
• W2993261710 startingPage "146" @default.
• W2993261710 abstract "Background: Based on pilot study data demonstrating safety and excellent survival [Blood 2014 124:46] in acute leukemia patients undergoing myeloablative cord blood transplant (CBT) plus infusion of an off-the-shelf non-HLA matched expanded CB unit (OTS) for bridging hematopoiesis, a randomized trial was conducted to determine whether myeloablative CBT with or without an OTS would confer more rapid neutrophil (ANC) engraftment and therefore a survival advantage. Methods: We conducted a multi-center, randomized controlled phase II trial (RCT) with a primary endpoint of ANC engraftment defined as the first of 2 consecutive days in which neutrophil count ≥ 500 cells/μL. Secondary endpoints included platelet engraftment, overall survival (OS), disease free-survival (DFS), acute/chronic graft-versus-host disease (GVHD), non-relapse mortality (NRM), and relapse. 160 patients were enrolled between February 2013 and June 2018. Patients were randomized to receive either a conventional single or double CBT (SOC group) (n=78) or SOC + OTS (OTS group) (n=82). Unmanipulated CB units had to be at least 4/6 HLA-matched to the patient (intermediate resolution for HLA-A, -B and allele-level for HLA-DRB1) with no HLA matching required for the OTS. Patient disease (AML=68, ALL=77, MDS=7, CML/other=8), disease risk, gender, age, race, ethnicity, CMV serology, performance score and HLA-match were balanced between the two study groups. Patients received conditioning with either FLU 75mg/m2, TBI 13.2 Gy, CY120 mg/kg or with FLU 150mg/m2, TBI 4Gy, CY 50 mg/kg and Thiotepa 10 mg/kg. Cyclosporin and MMF were used for GVHD prophylaxis in all patients (Table 1). Results: The median follow-up of surviving patients was 15 months. Approximately 30% of patients enrolled were &lt;18 years and most patients received the high dose TBI (13.2Gy) regimen (85% in OTS group and 91% in SOC group). The median pre-cryopreserved total nucleated cell dose was 5.4 × 107/kg for both groups while the median pre-cryopreserved CD34 cell dose was 0.30 and 0.28 × 106/kg for the OTS and SOC group, respectively. Patients in the OTS group received an additional median CD34+ cell dose of 10.5x106/kg. Median time to ANC engraftment was similar between the 2 groups, at 20 days (range 7-46) in the OTS group and 19 days (13-51) in the SOC group. Five patients experienced graft failure, 2 in the OTS group and 3 in the SOC group. Similarly, no difference was seen for median time to platelet engraftment [38 days (35-43) vs. 40 days (30-42) for the OTS and the SOC group]. Peripheral blood chimerisms performed weekly (day 7-28) revealed that the initial circulating myelomonocytes present in the peripheral blood of OTS patients at day 7 were nearly all generated from the OTS product. Contribution to engraftment of the OTS graft was transient, and generally undetectable after day 21. All outcomes were similar between the two groups. OS and DFS at 2 years were 70% and 60% vs 61% and 55% for the OTS and the SOC groups, respectively. Cumulative incidence of relapse and NRM at 2 years were 18% and 21% in the OTS group and 21% and 22% in the SOC group. Grade III-IV aGVHD was 16% and 14% for the and the SOC group, respectively. The OTS product was well tolerated, and serious adverse events rates similar between the 2 groups. Patients continue to be followed through 2 years to assess cGVHD, and graft-relapse-free-survival. Conclusion: In this multi-center RCT, no significant difference was observed in the primary or secondary endpoints. Importantly, while the median time to ANC recovery in the OTS group was unchanged (20 days) from our pilot study, the observed time to neutrophil recovery in the SOC group was 7 days quicker than expected based on previously observed outcomes following myeloablative CBT (median 26 days). During the 5 years that this study was open to accrual, the criteria for CB donor selection have improved, now regularly utilizing CD34+ cell content and high-resolution HLA-typing where available, as has the quality of the CB inventory. This RCT highlights that delayed engraftment should no longer be a barrier in the consideration of SOC CBT for patients with hematological malignancies. As expected, and observed consistently following CBT, both groups demonstrated low incidence of severe acute GVHD and relapse at 2 years. Interventions in CBT should focus on improving immune reconstitution and reducing the risk of NRM but must be easily adopted into SOC in order to be adopted clinically. Disclosures Milano: ExCellThera: Research Funding; Amgen: Research Funding. Rezvani:Kaleido: Membership on an entity's Board of Directors or advisory committees, Other: one-time compensation from advisory boards; Nohla Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other: one-time compensation from advisory boards; AbbVie: Other: Principal investigator ; U.S. Department of Justice: Other: Expert medical witness; Johnson & Johnson: Employment, Other: Brother is employed. Delaney:Nohla Therapeutics: Employment, Equity Ownership; Biolife Solutions: Membership on an entity's Board of Directors or advisory committees." @default.
• W2993261710 created "2019-12-13" @default.
• W2993261710 creator A5000429690 @default.
• W2993261710 creator A5025632410 @default.
• W2993261710 creator A5033267787 @default.
• W2993261710 creator A5041615072 @default.
• W2993261710 creator A5042490892 @default.
• W2993261710 creator A5046635472 @default.
• W2993261710 creator A5049744314 @default.
• W2993261710 creator A5055685996 @default.
• W2993261710 creator A5060384074 @default.
• W2993261710 creator A5069809093 @default.
• W2993261710 creator A5072539716 @default.
• W2993261710 date "2019-11-13" @default.
• W2993261710 modified "2023-09-30" @default.
• W2993261710 title "No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial" @default.
• W2993261710 doi "https://doi.org/10.1182/blood-2019-130716" @default.
• W2993261710 hasPublicationYear "2019" @default.
• W2993261710 type Work @default.
• W2993261710 sameAs 2993261710 @default.
• W2993261710 citedByCount "2" @default.
• W2993261710 countsByYear W29932617102020 @default.
• W2993261710 crossrefType "journal-article" @default.
• W2993261710 hasAuthorship W2993261710A5000429690 @default.
• W2993261710 hasAuthorship W2993261710A5025632410 @default.
• W2993261710 hasAuthorship W2993261710A5033267787 @default.
• W2993261710 hasAuthorship W2993261710A5041615072 @default.
• W2993261710 hasAuthorship W2993261710A5042490892 @default.
• W2993261710 hasAuthorship W2993261710A5046635472 @default.
• W2993261710 hasAuthorship W2993261710A5049744314 @default.
• W2993261710 hasAuthorship W2993261710A5055685996 @default.
• W2993261710 hasAuthorship W2993261710A5060384074 @default.
• W2993261710 hasAuthorship W2993261710A5069809093 @default.
• W2993261710 hasAuthorship W2993261710A5072539716 @default.
• W2993261710 hasConcept C126322002 @default.
• W2993261710 hasConcept C141071460 @default.
• W2993261710 hasConcept C168563851 @default.
• W2993261710 hasConcept C203014093 @default.
• W2993261710 hasConcept C203092338 @default.
• W2993261710 hasConcept C2776694085 @default.
• W2993261710 hasConcept C2776755627 @default.
• W2993261710 hasConcept C2776955114 @default.
• W2993261710 hasConcept C2777408962 @default.
• W2993261710 hasConcept C2779968505 @default.
• W2993261710 hasConcept C2779972918 @default.
• W2993261710 hasConcept C2908824208 @default.
• W2993261710 hasConcept C2911091166 @default.
• W2993261710 hasConcept C71924100 @default.
• W2993261710 hasConcept C90924648 @default.
• W2993261710 hasConceptScore W2993261710C126322002 @default.
• W2993261710 hasConceptScore W2993261710C141071460 @default.
• W2993261710 hasConceptScore W2993261710C168563851 @default.
• W2993261710 hasConceptScore W2993261710C203014093 @default.
• W2993261710 hasConceptScore W2993261710C203092338 @default.
• W2993261710 hasConceptScore W2993261710C2776694085 @default.
• W2993261710 hasConceptScore W2993261710C2776755627 @default.
• W2993261710 hasConceptScore W2993261710C2776955114 @default.
• W2993261710 hasConceptScore W2993261710C2777408962 @default.
• W2993261710 hasConceptScore W2993261710C2779968505 @default.
• W2993261710 hasConceptScore W2993261710C2779972918 @default.
• W2993261710 hasConceptScore W2993261710C2908824208 @default.
• W2993261710 hasConceptScore W2993261710C2911091166 @default.
• W2993261710 hasConceptScore W2993261710C71924100 @default.
• W2993261710 hasConceptScore W2993261710C90924648 @default.
• W2993261710 hasIssue "Supplement_1" @default.
• W2993261710 hasLocation W29932617101 @default.
• W2993261710 hasOpenAccess W2993261710 @default.
• W2993261710 hasPrimaryLocation W29932617101 @default.
• W2993261710 hasRelatedWork W2318530450 @default.
• W2993261710 hasRelatedWork W2359804617 @default.
• W2993261710 hasRelatedWork W2365848850 @default.
• W2993261710 hasRelatedWork W2392641532 @default.
• W2993261710 hasRelatedWork W2442220036 @default.
• W2993261710 hasRelatedWork W2590912865 @default.
• W2993261710 hasRelatedWork W3011439178 @default.
• W2993261710 hasRelatedWork W3029666843 @default.
• W2993261710 hasRelatedWork W4247148241 @default.
• W2993261710 hasRelatedWork W2114487924 @default.
• W2993261710 hasVolume "134" @default.
• W2993261710 isParatext "false" @default.
• W2993261710 isRetracted "false" @default.
• W2993261710 magId "2993261710" @default.
• W2993261710 workType "article" @default.